What is MID Labs?
MID Labs stands as a global leader in the development and manufacture of ophthalmic surgical devices, with a particular specialization in vitrectomy technology. The company's comprehensive product portfolio, featuring innovations such as Vitreous Cutters and the Single-Step Cannula Insertion System, has achieved distribution in over 30 countries. Driven by a commitment to research, innovation, and high-quality manufacturing, MID Labs focuses on creating medical devices designed to combat blindness stemming from various diseases and injuries, thereby enhancing patient outcomes worldwide.
How much funding has MID Labs raised?
MID Labs has raised a total of $51M across 1 funding round:
Unspecified
$51M
Unspecified (2014): $51M with participation from Softbank China Venture Capital, Frontline BioVentures, and OrbiMed Advisors, LLC
Key Investors in MID Labs
Softbank China Venture Capital
Softbank China Venture Capital is a leading venture capital and private equity firm established in China, focusing on high-growth companies across TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors. They invest across all company stages and provide capital and strategic support to help portfolio companies achieve their potential.
Frontline BioVentures
Frontline BioVentures is a venture capital firm with deep expertise and a broad network in China's life sciences industry. With offices in Shanghai, Suzhou, and Hong Kong, they are an active investor in innovative biopharmaceuticals and medical devices.
OrbiMed Advisors, LLC
OrbiMed Advisors LLC is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They possess extensive experience in life sciences and healthcare business development, supporting companies from early-stage ventures to established organizations.
What's next for MID Labs?
The substantial enterprise-level funding and recent strategic investment signal a new phase of accelerated growth and innovation for MID Labs. This capital is expected to fuel further research and development into cutting-edge ophthalmic solutions, expand global market reach, and potentially support strategic acquisitions or partnerships. The company's focus on preventing blindness through advanced medical devices positions it for continued leadership and impact within the healthcare industry.
See full MID Labs company page
